Athira pharma to present data supporting therapeutic potential of enhancing hgf/met neurotrophic system at upcoming scientific conferences

Bothell, wash., march 06, 2023 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in two upcoming scientific conferences: american society for experimental neurotherapeutics (asent) 2023 annual meeting, which will be held virtually from mar. 13-15, 2023, and ad/pd™ 2023 international conference on alzheimer's and parkinson's diseases (ad/pd), which will be held in gothenburg, sweden and virtually from mar. 28-apr. 1, 2023.
ATHA Ratings Summary
ATHA Quant Ranking